Hudson Valley Investment Advisors Inc. ADV Grows Position in Danaher Co. (NYSE:DHR)

Hudson Valley Investment Advisors Inc. ADV lifted its stake in Danaher Co. (NYSE:DHR) by 22.7% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 46,106 shares of the conglomerate’s stock after buying an additional 8,526 shares during the quarter. Danaher accounts for approximately 1.4% of Hudson Valley Investment Advisors Inc. ADV’s holdings, making the stock its 19th largest position. Hudson Valley Investment Advisors Inc. ADV’s holdings in Danaher were worth $12,818,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Danaher by 7.4% in the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after acquiring an additional 4,163,657 shares during the period. Swedbank AB acquired a new position in shares of Danaher during the first quarter valued at about $676,545,000. TD Asset Management Inc increased its holdings in shares of Danaher by 99.0% during the second quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock valued at $339,473,000 after acquiring an additional 675,952 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of Danaher by 22.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock valued at $761,475,000 after acquiring an additional 563,546 shares in the last quarter. Finally, International Assets Investment Management LLC increased its holdings in shares of Danaher by 40,196.5% during the third quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after acquiring an additional 428,897 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Activity at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 11.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on DHR. Barclays cut their price target on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Wells Fargo & Company began coverage on shares of Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price target on the stock. Royal Bank of Canada cut their price target on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. TD Cowen increased their price target on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Finally, The Goldman Sachs Group increased their price target on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Six equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average price target of $287.16.

Danaher Price Performance

Shares of NYSE DHR opened at $242.32 on Thursday. Danaher Co. has a twelve month low of $188.75 and a twelve month high of $281.70. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $179.48 billion, a price-to-earnings ratio of 41.07, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. The business has a 50 day simple moving average of $267.83 and a 200-day simple moving average of $260.42.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the previous year, the business earned $2.02 EPS. The business’s quarterly revenue was up 3.1% on a year-over-year basis. As a group, equities research analysts expect that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were given a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. Danaher’s dividend payout ratio is currently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.